GeneDx Raises $33M to End the Diagnostic Odyssey and Empower Patient-Centric Genetic Care

GeneDx is thrilled to announce a significant funding milestone, having raised $33,000,000 in our latest round of financing.

This investment marks a pivotal moment in our journey toward reshaping the landscape of genetic testing and care.

At GeneDx, we envision a world where every genetic condition is understood, and every patient receives the care they need to live their fullest life.

Our unique approach to genetic testing, supported by one of the world’s most diverse rare disease data sets, positions us as a catalyst for clear, connected, and actionable care.

With this new infusion of capital, we are poised to accelerate our mission to end the diagnostic odyssey that many patients face today.

The funding will empower us to enhance our state-of-the-art testing technologies, broaden our research and development initiatives, and expand our reach in underserved markets.

By building on our legacy as one of Fast Company's Most Innovative Companies of 2025, we are committed to leveraging this support to further integrate advanced data analytics and personalized medicine into routine clinical practice.

Our goal is to make a transformative impact on patient care by ensuring that every genetic test not only delivers precise results but also connects patients with the resources and treatments essential for improving their quality of life.

This investment reinforces our steadfast commitment to pioneering innovations that bridge the gap between genetic insights and effective, tangible healthcare solutions.

At GeneDx, we believe that every breakthrough begins with a single test, and with this new milestone, we are one step closer to a future where the complexities of genetic conditions are fully unraveled and managed through compassionate, evidence-based care.